Masako Mishima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masako Mishima has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Haruhiko Takeda
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University , 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507
4 shared publications - Atsushi Takai
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3 shared publications - Yuji Eso
Department of Gastroenterology and Hepatology, Graduate School of Medicine Kyoto University Kyoto Japan
3 shared publications - Eriko Iguchi
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 shared publications Hiroshi Seno
Department of Gastroenterology and Hepatology Graduate School of Medicine Kyoto University Kyoto Japan
2 shared publications- Hiroshi Seno
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
2 shared publications
Latest Publications
- 13 September 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (1) , 100-110
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study
Aim: Atezolizumab plus bevacizumab (Atezo+Bev) therapy is the preferred first‐line treatment for advanced hepatocellular carcinoma (HCC). However, the efficacy of Atezo+Bev is limited in patients with a CRAFITY score of 2 (C‐reactive protein ≥ 1 mg/dL and alpha‐fetoprotein [AFP] ≥ 100 ng/mL). This study compared the efficacy and safety of lenvatinib and Atezo+Bev in these patients. Methods: We retrospectively analyzed 774 patients treated with lenvatinib or Atezo+Bev as first‐line treatment for advanced HCC between October 2020 and December 2023 across 11 hospitals in Japan. Among them, 90 patients (11.6%) had a CRAFITY score of 2. Progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profiles were compared. Results: Baseline characteristics were similar, except tumor size and AFP levels, which were higher in the Atezo+Bev group. Median PFS was significantly longer in the lenvatinib group compared to the Atezo+Bev group (6.0 vs. 2.3 months; hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.32–0.95]; p = 0.032). The median OS was not significantly different between the two groups (9.8 vs. 5.2 months; HR: 0.66, 95% CI: 0.41–1.08; p = 0.101). The DCR (62.0% vs. 30.0%; p = 0.003) and the occurrence of grade ≥ 3 treatment‐related adverse events (46.0% vs. 20.0%; p = 0.014) were significantly higher in the lenvatinib group than in the Atezo+Bev group. Conclusion: Lenvatinib provided a significantly longer PFS than Atezo+Bev in patients with HCC and a baseline CRAFITY score of 2, whereas OS did not significantly differ between the two groups. These findings may serve as a cornerstone for developing biomarker‐based strategies in first‐line treatment selection for this patient population.
- 13 September 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (1) , 100-110
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study
Aim: Atezolizumab plus bevacizumab (Atezo+Bev) therapy is the preferred first‐line treatment for advanced hepatocellular carcinoma (HCC). However, the efficacy of Atezo+Bev is limited in patients with a CRAFITY score of 2 (C‐reactive protein ≥ 1 mg/dL and alpha‐fetoprotein [AFP] ≥ 100 ng/mL). This study compared the efficacy and safety of lenvatinib and Atezo+Bev in these patients. Methods: We retrospectively analyzed 774 patients treated with lenvatinib or Atezo+Bev as first‐line treatment for advanced HCC between October 2020 and December 2023 across 11 hospitals in Japan. Among them, 90 patients (11.6%) had a CRAFITY score of 2. Progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profiles were compared. Results: Baseline characteristics were similar, except tumor size and AFP levels, which were higher in the Atezo+Bev group. Median PFS was significantly longer in the lenvatinib group compared to the Atezo+Bev group (6.0 vs. 2.3 months; hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.32–0.95]; p = 0.032). The median OS was not significantly different between the two groups (9.8 vs. 5.2 months; HR: 0.66, 95% CI: 0.41–1.08; p = 0.101). The DCR (62.0% vs. 30.0%; p = 0.003) and the occurrence of grade ≥ 3 treatment‐related adverse events (46.0% vs. 20.0%; p = 0.014) were significantly higher in the lenvatinib group than in the Atezo+Bev group. Conclusion: Lenvatinib provided a significantly longer PFS than Atezo+Bev in patients with HCC and a baseline CRAFITY score of 2, whereas OS did not significantly differ between the two groups. These findings may serve as a cornerstone for developing biomarker‐based strategies in first‐line treatment selection for this patient population.
- Open Access
- 27 September 2024
- Published by Wiley in The Journal of Pathology
- Vol. 264 (3) , 318-331
TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential
Telomerase reverse transcriptase (TERT) gene aberration is detectable in >80% of cases with hepatocellular carcinoma (HCC). TERT reactivation is essential for cellular immortalization because it stabilizes telomere length, although the role of TERT in hepatocarcinogenesis remains unelucidated. To elucidate the significance of aberrant TERT expression in hepatocytes in inflammation‐associated hepatocarcinogenesis, we generated Alb‐Cre;TertTg mice, which overexpress TERT in the liver and examined their phenotype during chronic inflammation. Based on transcriptome data from the liver tissue of Alb‐Cre;TertTg mice, we examined the role of TERT in hepatocarcinogenesis in vitro. We also evaluated the relationship between TERT and cell‐cycle‐related molecules, including p21, in HCC samples. The liver tumor development rate was increased by TERT overexpression during chronic inflammation, especially in the absence of p53 function. Gene set enrichment analysis of liver tissues revealed that gene sets related to TNF‐NFκB signaling, cell cycle, and apoptosis were upregulated in Alb‐Cre;TertTg liver. A luciferase reporter assay and immunoprecipitation revealed that TERT interacted with NFκB p65 and enhanced NFκB promoter activity. On the other hand, TERT formed protein complexes with p21, cyclin A2, and cyclin E and promoted ubiquitin‐mediated degradation of p21, specifically in the G1 phase. In the clinical HCC samples, TERT was highly expressed but p21 was conversely downregulated, and TERT expression was associated with the upregulation of molecules related to the cell cycle. Taken together, the aberrant upregulation of TERT increased NFκB promoter activity and promoted cell cycle progression via p21 ubiquitination, leading to hepatocarcinogenesis. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 27 September 2024
- Published by Wiley in The Journal of Pathology
- Vol. 264 (3) , 318-331
Open AccessTERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential
Telomerase reverse transcriptase (TERT) gene aberration is detectable in >80% of cases with hepatocellular carcinoma (HCC). TERT reactivation is essential for cellular immortalization because it stabilizes telomere length, although the role of TERT in hepatocarcinogenesis remains unelucidated. To elucidate the significance of aberrant TERT expression in hepatocytes in inflammation‐associated hepatocarcinogenesis, we generated Alb‐Cre;TertTg mice, which overexpress TERT in the liver and examined their phenotype during chronic inflammation. Based on transcriptome data from the liver tissue of Alb‐Cre;TertTg mice, we examined the role of TERT in hepatocarcinogenesis in vitro. We also evaluated the relationship between TERT and cell‐cycle‐related molecules, including p21, in HCC samples. The liver tumor development rate was increased by TERT overexpression during chronic inflammation, especially in the absence of p53 function. Gene set enrichment analysis of liver tissues revealed that gene sets related to TNF‐NFκB signaling, cell cycle, and apoptosis were upregulated in Alb‐Cre;TertTg liver. A luciferase reporter assay and immunoprecipitation revealed that TERT interacted with NFκB p65 and enhanced NFκB promoter activity. On the other hand, TERT formed protein complexes with p21, cyclin A2, and cyclin E and promoted ubiquitin‐mediated degradation of p21, specifically in the G1 phase. In the clinical HCC samples, TERT was highly expressed but p21 was conversely downregulated, and TERT expression was associated with the upregulation of molecules related to the cell cycle. Taken together, the aberrant upregulation of TERT increased NFκB promoter activity and promoted cell cycle progression via p21 ubiquitination, leading to hepatocarcinogenesis. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
- 1 June 2021
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 11 (6) , 2766-2774
A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles
Contrast-enhanced computed tomography (CECT) is generally used to evaluate the response to treatment of hepatocellular carcinoma (HCC); however, CECT is unsuitable for the early prediction of therapeutic effects and frequent monitoring. We aimed to investigate the usefulness of our simplified method for the quantification of tumor vascularity using contrast-enhanced ultrasound (CEUS) with perfluorobutane microbubbles [Sonazoid® (GE Healthcare, Oslo, Norway)] to predict the therapeutic effect of lenvatinib. Among the 13 patients studied, nine who had more than a 20% reduction in tumor vascularity within 2 weeks of starting treatment experienced complete response or partial response at 8–12 weeks as assessed by CECT. In contrast, three patients without reductions and one patient with only a slight decrease in tumor vascularity had a poor response to lenvatinib. Quantitative assessment of tumor vascularity by our simplified CEUS-based method could be a useful predictor of therapeutic responses to lenvatinib in patients with HCC.
- 1 June 2021
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 11 (6) , 2766-2774
Open AccessA simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles
Contrast-enhanced computed tomography (CECT) is generally used to evaluate the response to treatment of hepatocellular carcinoma (HCC); however, CECT is unsuitable for the early prediction of therapeutic effects and frequent monitoring. We aimed to investigate the usefulness of our simplified method for the quantification of tumor vascularity using contrast-enhanced ultrasound (CEUS) with perfluorobutane microbubbles [Sonazoid® (GE Healthcare, Oslo, Norway)] to predict the therapeutic effect of lenvatinib. Among the 13 patients studied, nine who had more than a 20% reduction in tumor vascularity within 2 weeks of starting treatment experienced complete response or partial response at 8–12 weeks as assessed by CECT. In contrast, three patients without reductions and one patient with only a slight decrease in tumor vascularity had a poor response to lenvatinib. Quantitative assessment of tumor vascularity by our simplified CEUS-based method could be a useful predictor of therapeutic responses to lenvatinib in patients with HCC.
- Open Access
- 1 March 2020
- Published by Japan Society of Hepatology in Kanzo
- Vol. 61 (3) , 129-132
Usefulness of dose intensity/body surface area ratio (DI/BSA ratio; DBR) rather than relative dose intensity in the lenvatinib treatment for hepatocellular carcinoma
Relative dose intensity (RDI) is the ratio between the delivered dose intensity and the standard dose. Maintaining high RDI has been shown to improve clinical outcomes in various cancers. The dose of lenvatinib was determined according to patient's weight (12 mg/day for ≥60 kg or 8 mg/day for p = 0.0534) was not significant, whereas patients with high DBR (≥240) showed significantly better PFS than those with low DBR (p < 0.0001). DBR may be more appropriately used in assessing the lenvatinib treatment intensity as compared with RDI.
- 1 March 2020
- Published by Japan Society of Hepatology in Kanzo
- Vol. 61 (3) , 129-132
Open AccessUsefulness of dose intensity/body surface area ratio (DI/BSA ratio; DBR) rather than relative dose intensity in the lenvatinib treatment for hepatocellular carcinoma
Relative dose intensity (RDI) is the ratio between the delivered dose intensity and the standard dose. Maintaining high RDI has been shown to improve clinical outcomes in various cancers. The dose of lenvatinib was determined according to patient's weight (12 mg/day for ≥60 kg or 8 mg/day for p = 0.0534) was not significant, whereas patients with high DBR (≥240) showed significantly better PFS than those with low DBR (p < 0.0001). DBR may be more appropriately used in assessing the lenvatinib treatment intensity as compared with RDI.